Neurite Outgrowth Assay


Assessment of neurite outgrowth using a high content screening platform:

  • The neurite outgrowth assay uses human iPSC-derived neurons (other cell types available upon request).
  • Cyprotex’s neurite outgrowth assay uses high content screening (HCS) technology to monitor neurite outgrowth.
  • Neurons are plated on laminin-coated 384-well plates 1 hour prior to treatment. After treatment with test articles and control compounds, neurons are maintained in a humidified environment at 37°C with 5% CO2 for 72 hrs (optimal). At the end of the treatment period, cells are fixed, permeabilized and stained for evaluation of neurite outgrowth and cell health.
  • This assay provides a viable in vitro system for assessing compounds that interfere or promote normal neurite outgrowth in neurons, providing a platform for preclinical drug safety, drug discovery and disease modeling.


Neurite Outgrowth Assay Protocol


Data from Cyprotex's Neurite Outgrowth Assay

Neurite outgrowth fig 1

Figure 1
Evaluation of cell health and neurite outgrowth for positive control nocodazole tested in human iPSC-derived neurons.
Positive control nocodazole causes a significant decrease in mean neurite average length and neurite total length per neuron over the range of concentrations tested. Nocodazole did not have significant effects on cell viability at these concentrations.

Neurite outgrowth fig 4

Figure 4
High content images of human iPSC-derived neurons after 72 hr treatment with 100 and 0.2µM chlorpromazine. At 100µM, chlorpromazine causes cell death. At the lowest concentration of 0.2µM, cell loss and neurite outgrowth are unaffected.


1) Salto R et al., (2015). ß-Hydroxy-ß-methylbutyrate (HMB) promotes neurite outgrowth neuro2a cells. PLoS One. 10(8); e0135614


Cyprotex eStore

Order our services online.

Visit the Cyprotex eStore

Contact Our Experts

Paul Walker

Paul Walker, PhD

VP Head of Toxicology & Innovation Efficiency

Logo Cyprotex white
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.